Your session is about to expire
← Back to Search
Radiation + Standard Care for Metastatic Prostate Cancer
Study Summary
This trial will see if adding radiation to the current standard of care for prostate cancer that has spread to a few other parts of the body improves how well the treatment works.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have brain metastases.My prostate cancer is confirmed to be small cell or neuroendocrine type.My prostate cancer has spread to 5 or fewer areas that can be targeted with radiation.My doctor says I need urgent radiation for my tumor.Doctors believe that you have less than 3 months to live.I am 18 years old or older.My prostate cancer was confirmed by a biopsy.I haven't had cancer, except for certain skin, bladder, or head and neck cancers, in the last 3 years.I do not have any unmanaged ongoing illnesses.I've stopped all previous cancer treatments except for hormone therapy, unless I've just started a new one for advanced prostate cancer within the last 14 days.My prostate cancer is worsening despite low testosterone levels.My doctor says I'm fit for radiotherapy and systemic therapy.I cannot have radiotherapy, systemic treatment, CTs, or bone scans.I am scheduled for treatment with Radium-223 or sipuleucel-T.I am able to care for myself and perform daily activities.
- Group 1: Standard of Care + Ablative Radiation
- Group 2: Standard of Care
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment actively seeking out participants?
"This trial is not currently seeking participants. It was first posted on December 10th 2018 and updated last on October 28th 2022. For those interested in other clinical trials, there are 1315 studies open to prostate cancer patients and 479 concerning Ablative Radiation Therapy that have yet to reach capacity."
What is the current enrollment size of this experiment?
"This trial is not open for enrollment at present. It was originally posted on December 10th 2018 with the last update occurring on October 28th 2022. For those looking to participate in a related study, there are currently 1315 trials recruiting patients with prostate cancer and 479 studies searching for participants who can undergo Ablative Radiation Therapy."
Could you please enumerate other trials that have investigated the efficacy of Ablative Radiation Therapy?
"Presently, 479 Ablative Radiation Therapy clinical trials are in progress with 164 of those investigations having reached Phase 3. Numerous studies pertaining to this intervention have begun in Germantown, Tennessee but there exists a total of 31352 locations conducting research on Ablative Radiation Therapy."
Has Ablative Radiation Therapy been validated by the FDA?
"Ablative Radiation Therapy is estimated to have a safety score of 2, as this Phase 2 trial has demonstrated some evidence for its security but lacks scientific proof in regards to its efficacy."
What maladies do physicians typically employ Ablative Radiation Therapy to treat?
"Ablative Radiation Therapy is primarily utilized to treat cancerous neoplasms, yet it has also been successful in treating other conditions including advance directives, sarcoma, and malignant esophageal tumours."
Share this study with friends
Copy Link
Messenger